Report: Johnson & Johnson: Pipeline, Products, Performance, Potential TOC

Principal Operating Results

Johnson & Johnson

Executive Summary

Introduction
- Current Growth Drivers
- Key Late-Stage Products
Financial Performance 2005
- Sales and Market Position
- Income
  - Sales, Costs and Operating Income, 2005
- Expenditure
  - Capital Expenditure
  - Capital Expenditure By Business Area
  - Capital Expenditure By Business Area, 2005
  - R&D Expenditure
  - Pharmaceutical R&D To Total R&D
  - Pharma R&D and Pharma R&D to Pharma Sales
- Divisional Performance
  - Sales By Business Area
  - Sales By Business Area
  - Operating Profit By Business Area
  - Operating Profit By Business Area
  - Identifiable Assets By Business Area
  - Identifiable Assets By Business Area
- Geographic Performance
  - Sales By Destination
  - Sales By Destination
  - Long-Lived Assets By Geographical Area
  - Long-Lived Assets By Geographical Area
Company Strategy
- Mergers, Acquisitions and Divestitures
  - Medical Devices and Diagnostics Segment
  - Pharmaceutical Segment
  - Consumer Segment
- Key Agreements
Product / R&D Overview
- Key Products
  - Recent Product Launches
  - Recent Product Approvals
- R&D Strategy
  - Key R&D projects
- R&D Pipeline Overview
- Sales Forecasts
  - Sales of Current Top Ten Products (2000A-2010E)
Conclusions

PRODUCT PORT FOLIO / RESEARC H AND DEVELOPMENT

Major Pharmaceutical Products, Therapeutic Areas and Sales
Sales of Major Pharmaceutical Products, 2005
R&D Pipeline

Central Nervous System - Products
- Major Launched Products
- Risperdal
  - Sales
  - Key Markets/Indications/Formulations
  - Generic Competition/Lawsuits
  - Safety Issues
  - Sales Forecast
- Risperdal Sales (2000A-2010E)
  - Clinical Trial Results - Autism
- Duragesic/Ionsys
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Competitor Products
  - Generic Competition
  - Lawsuits
  - Safety Issues
  - Sales Forecast
- Duragesic Sales (2000A-2010E)
- Topamax
  - Mode of Action
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Competitor Products
  - Safety Information
  - Sales Forecast
  - Clinical Trial Results
- Ultram/Ultracet
  - Markets/Indications/Formulations
  - Generic Competition
- Razadyne
  - Mode of Action
  - Key Markets/Indications/Formulations
  - Competitor Products
  - Lawsuits
  - Safety Issues
- Concerta
  - Sales
  - Safety Studies
  - Generic Competition
  - Clinical Trials
Central Nervous System - R&D
- OROS hydromoprhone
- Paliperidone
  - Clinical Trial Results
- Tapentadol
Central Nervous System - Summary
Gastrointestinal - Products
- Major Launched Products
- Pariet/Aciphex
  - Sales
  - Key Markets/Indications
  - Competitor Products
  - Sales Forecast
- Aciphex/Pariet Sales (2000A-2010E)
- Others
Gastrointestinal - Summary
Immunology - Products
- Major Launched Products
- Remicade (TA-650)
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Safety Issues
  - Sales Forecast
- Remicade Sales (2000A-2010E)
  - Clinical Trial Results - Paediatric Crohn's Disease
- Orthoclone OKT3
Immunology - R&D
- CNTO 1275
- Golimumab
  - Clinical Trial Results
Immunology - Summary
Haematology - Products
- Major Launched Products
- Eprex/Procrit
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Safety Information
  - Sales Forecast
- Eprex/Procrit Sales (2000A-2010E)
  - Clinical Trial Results
Haematology - R&D
- ICA-17043
  - Clinical Trial Results
Haematology - Summary
Anti-infective - Products
- Major Launched Products
- Floxin
  - Key Markets/Indications/Formulations
  - Generic Competition
- Levaquin
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Generic Competition
  - Sales Forecast
- Levaquin/Floxin Sales (2000A-2010E)
- Sporanox/Itrizole
  - Sales
  - Key Markets/Indications/Formulations
  - Generic Competition
  - Sales Forecast
- Sporanox Sales (2000A-2010E)
Anti-infective - R&D
- Ceftobiprole
  - Clinical Trials
- Doripenem
- TMC114
  - Clinical Trial Results
- TMC125
  - evelopment Status
Anti-infective - Summary
Oncology - Products
- Doxil/Caelyx
  - Key Markets/Indications/Formulations
  - Further Development
  - Patents/Lawsuits
  - Clinical Trial Results
- Velcade
  - Key Markets/Indications/Formulations
  - Further Development
  - Clinical Trial Results - Lymphoma
- Others
Oncology - R&D
- Anti-IL-6 MAb
- UHRF1
- Yondelis
  - Clinical Trial Results
- Zarnestra
Oncology - Summary
Cardiovascular - Products
- Retavase
  - Key Markets/Indications/Formulations
  - Clinical Trial Results
- ReoPro
  - Key Markets/Indications/Formulations
  - Further Development
  - Safety Issues
- Natrecor
  - Key Markets/Indications/Formulations
  - Further Development
  - Lawsuits
  - Safety Issues
  - Clinical Trial Results
Cardiovascular R&D
- BAY 59-7939
Cardiovascular - Summary
Reproductive Health - Products
- Ortho Evra
  - Mode Of Action
  - Key Markets/Indications/Formulations
  - Safety Issues
Reproductive Health - R&D
- Dapoxetine
  - Clinical Trial Results
Reproductive Health - Summary
Other - R&D
- APD668

APPENDIX 1 - FINANCIA L PERFORMA NCE

Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity

APPENDIX 2 - KEY AGREEMENTS

Ablynx
- 11th January 2006
AdipoGenix Inc
- 17th December 2002
Amgen
- 18th October 2002
- 24th January 2003
- 12th December 1996
- 1st January 1997
- 18th January 2006
Arena Pharmaceuticals Inc
- 21st December 2004
- 23rd December 2004
- 11th August 2005
- 7th February 2006
Barrier Therapeutics
- 10th May 2002
- 22nd September 2005
Basilea Pharmaceutica AG
- 3rd February 2005
Bayer
- 5th April 2000
- 10th May 2000
- 26th October 2005
Biovail Corporation International
- 15th September 1998
- 3rd November 2005
- 2nd December 2005
Cara Therapeutics Inc
- 5th January 2006
Cellzome Inc
- 16th March 2005
- 23rd May 2005
Crucell NV
- 24th December 2002
- 16th January 2003
- 23rd November 2005
Curis Inc
- 15th December 2005
Eisai
- 15th April 1997
- 16th March 2000
- 7th January 2004
Eli Lilly
Entelos Inc
- 16th March 2006
Ferring Pharmaceuticals Inc
- 30th October 2002
GlaxoSmithKline
- 12th July 2000
- 7th January 2002
- 20th July 2005
Grunenthal GmbH
- 10th October 2003
- 28th April 2006
GTx Inc
- 17th March 2004
Icagen Inc
- 29th June 2004
ImClone Systems Inc
- 26th January 2005
ImmunoGen Inc
- 28th December 2004
- 29th March 2004
Kyowa Hakko
Medivir AB
- 29th December 2005
Mitsubishi Pharma Corporation
- 26th October 1998
Millennium Pharmaceuticals Inc
- 27th September 1996
- 30th June 2003
- 9th March 2006
Morphosys
- 25th March 2002
- 14th August 2002
- 11th November 2002
- 31st July 2003
- 8th March 2004
- 15th April 2004
- 25th August 2004
- 23rd December 2004
- 6th September 2005
- 28th February 2006
Mylan Pharmaceuticals Inc
- 20th December 2005
Neurochem Inc
- 22nd December 2004
- 13th February 2006
- 18th April 2006
Paradigm Therapeutics Ltd
- 30th June 2005
Pamgene International BV
- 9th March 2006
Pharmaceutical Product Development(PPD)
- 5th January 2004
Roche/Dade Behring
- 13th March 1998
Sangamo BioSciences Inc
- 6th June 2000
- 30th September 2004
- 15th December 2004
- 14th September 2005
Sepracor Inc
- 21st July 1998
Serono
- 13th July 2000
Shire Pharmaceuticals/Synaptec Inc
- 30th November 1995
- 16th January 1996
- 1st April 2004
Taisho Pharmaceutical Co Ltd
- 17th December 2004
Theratechnologies
- 3rd May 2001
- 17th December 2001
- 12th September 2002
- 25th September 2002
- 4th September 2003
- 21st December 2004
Zeltia Group
- 10th August 2001
- 16th October 2001

APPENDIX 3 - INFRASTRUCTURE

Research and Development Facilities
Manufacturing Facilities

APPENDIX 4 - Key PHARMAC EUTICAL SUBSIDIARIES / JOINT VENTURES

Subsidiaries
Joint-Venture Companies

Johnson & Johnson: Pipeline, Products, Performance, Potential

Table of Contents

Executive Summary

PRODUCT PORT FOLIO / RESEARC H AND DEVELOPMENT

APPENDIX 1 - FINANCIA L PERFORMA NCE

APPENDIX 2 - KEY AGREEMENTS

APPENDIX 3 - INFRASTRUCTURE

APPENDIX 4 - Key PHARMAC EUTICAL SUBSIDIARIES / JOINT VENTURES

APPENDIX 5 - PRODUCT INDEX